|
End-of-day quote
Korea S.E.
11/09/2026
|
5-day change | 1st Jan Change | ||
| 109,300.00 KRW | +9.52% |
|
+13.97% | -22.15% |
Company Valuation: OliX Pharmaceuticals, Inc
Data adjusted to current consolidation scope
| Fiscal Period: December | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| Market Cap 1 | 355,531 | 2,834,660 | 2,302,170 | - |
| Change | - | 697.3% | -18.78% | - |
| Enterprise Value (EV) | 355,531 | 2,834,660 | 2,302,170 | 2,302,170 |
| Change | - | 697.3% | -18.78% | 0% |
| P/E | -7.98x | -176x | -70.6x | -72.6x |
| PBR | - | - | 36.4x | 37.6x |
| PEG | - | 2.6x | -0.8x | 26.14x |
| Capitalization / Revenue | - | 193x | 288x | 209x |
| EV / Revenue | - | 0x | 288x | 209x |
| EV / EBITDA | - | -0x | -79.4x | -82.2x |
| EV / EBIT | - | -0x | -74.3x | -76.7x |
| EV / FCF | - | - | -67.7x | -69.8x |
| FCF Yield | - | - | -1.48% | -1.43% |
| Dividend per Share 2 | - | - | - | - |
| Rate of return | - | - | - | - |
| EPS 2 | -2,414 | -800 | -1,548 | -1,505 |
| Distribution rate | - | - | - | - |
| Net sales 1 | - | 14.67 | 8 | 11 |
| EBITDA 1 | - | -27.52 | -29 | -28 |
| EBIT 1 | - | -30.46 | -31 | -30 |
| Net income 1 | -19.1 | -16.23 | -31 | -30 |
| Net Debt | - | - | - | - |
| Reference price 2 | 19,260.00 | 140,400.00 | 109,300.00 | 109,300.00 |
| Nbr of stocks (in thousands) | 18,460 | 20,190 | 21,063 | - |
| Announcement Date | 3/21/25 A | 2/12/26 A | - | - |
1KRW in Billions2KRW
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -70.61x | - | - | - | 1.72B | |
| 19.64x | 6.93x | 13.92x | 1.51% | 66.93B | |
| 31.94x | 9.24x | 44.54x | 0.04% | 61.97B | |
| -79.21x | 15.29x | -73.77x | -.--% | 28.26B | |
| 28.46x | 6.03x | 15.64x | -.--% | 24.59B | |
| -14.63x | 5.3x | -6.66x | -.--% | 24.3B | |
| 26.45x | 4.98x | 16.56x | -.--% | 19.41B | |
| 48.28x | 17.79x | 36.09x | 0.31% | 16.77B | |
| 1225.47x | 35.26x | 769.42x | -.--% | 14.18B | |
| -15x | 3382.33x | -17.29x | -.--% | 14B | |
| Average | 120.08x | 387.02x | 88.72x | 0.21% | 27.21B | |
| Weighted average by Cap. | 72.63x | 184.88x | 49.64x | 0.4% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- A226950 Stock
- Valuation OliX Pharmaceuticals, Inc
Select your edition
All financial news and data tailored to specific country editions
